<DOC>
	<DOCNO>NCT01745848</DOCNO>
	<brief_summary>Our primary hypothesis Roflumilast ( 500 Î¼cg , daily ) significantly decrease surrogate marker bone metabolism early cardiovascular disease individual moderate severe airflow obstruction chronic bronchitis phenotype .</brief_summary>
	<brief_title>Roflumilast Markers Bone Metabolism Endothelial Function COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Subjects age 50 70 minimum tenpack year tobacco exposure , airflow obstruction ( FEV1/FVC &lt; 0.70 ) FEV1 &lt; 70 % baseline sputum production least time report Saint George 's Respiratory Questionnaire , least one exacerbation within past year Subjects chronic prednisone use , antiresorptive therapy use ( bisphosphonates , calcitonin , parathyroid hormone ) Subjects body mass index less 18 great 34</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Roflumilast</keyword>
	<keyword>COPD</keyword>
</DOC>